Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Duchenne Muscular Dystrophy Treatment Market is expected to reach US$ 71.1 billion by 2034, growing at a CAGR of 42.10% from its estimated US$ 2.1 billion in 2024.

A severe form of muscular dystrophy, Duchenne muscular dystrophy is a hereditary condition. Muscle dystrophies are a class of illnesses that severely impair muscles, gradually making them weaker and less flexible. This hereditary disorder is caused by a mutation in the dystrophin gene, which produces the muscle protein.

The primary driver of the target market's expansion is the growing number of people with Duchenne muscular dystrophy. The rising frequency of human exposure to mutagens, such as radiation, many chemicals, and different pathogenic organisms, causes these harmful mutations. Eventually, this results in a growing need for secure and efficient medications and treatments to treat this illness, which in turn promotes the development of the market for treatments for Duchenne muscular dystrophy. For instance, one in every 3500 male babies born globally is said to have Duchenne muscular dystrophy, according to the National Organization for Rare Disorders. In total, this condition has impacted about 250,000 people since birth.